Forest Laboratories


Forest Labs to buy anti-arrhythmia drug from Blue Ash Therapeutics

Cincinnati-based Blue Ash Therapeutics has reached an agreement in which Forest Laboratories (NYSE:FRX) will purchase the rights to an anti-arrhythmia drug the Ohio firm has been developing. New York-based Forest didn’t release financial terms of the deal in a statement. Under the terms of the deal, Forest will be responsible for all future development and […]